rocaglamide profile

rocaglamide: RN refers to (1alpha,2alpha,3beta,3abeta,8bbeta)-isomer; isolated from stems of Aglaia elliptifolia; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

rocaglamide : An organic heterotricyclic compound that is 2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan substituted by hydroxy groups at positions 1 and 8b, methoxy groups at positions 6 and 8, a 4-methoxyphenyl group at position 3a, a phenyl group at position 3 and a N,N-dimethylcarbamoyl group at position 1. Isolated from Aglaia odorata and Aglaia duperreana, it exhibits antineoplastic activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Related Flora

Flora	Rank	Flora Definition	Family	Family Definition
Aglaia	genus	A plant genus of the family MELIACEAE. Members contain lariciresinol, pregnanes, insecticidal rocaglamide derivatives and other compounds.[MeSH]	Meliaceae	The mahogany plant family of the order Sapindales, subclass Rosidae, class Magnoliopsida.[MeSH]
Aglaia odorata	species	[no description available]	Meliaceae	The mahogany plant family of the order Sapindales, subclass Rosidae, class Magnoliopsida.[MeSH]

ID Source	ID
PubMed CID	331783
CHEMBL ID	438139
CHEBI ID	66309
SCHEMBL ID	752144
MeSH ID	M0280253

Synonym
smr001565405
c29h31no7
NCI60_002832
nsc-326408
mls002701812 ,
NSC326408 ,
84573-16-0
rocaglamide (fr aglaia elliptifolia)
1h-cyclopenta[b]benzofuran-2-carboxamide,3,3a,8b-tetrahydro-1,8b-dihydroxy-6,8-dimethoxy- 3a-(4-methoxyphenyl)-n,n-dimethyl-3-phenyl-, [1r-(1.alpha.,2.alpha.,3.beta.,3a.beta.,8b.beta.)]-
1h-cyclopenta[b]benzofuran-2-carboxamide,3,3a,8b-tetrahydro-1,8b-dihydroxy-6,8-dimethoxy- 3a-(4-methoxyphenyl)-n,n-dimethyl-3-phenyl-,(1r,2r,3s,3ar,8bs)-
rocaglamide
b603847k064
bdbm50196926
CHEMBL438139 ,
chebi:66309 ,
(1r,2r,3s,3ar,8bs)-1,8b-dihydroxy-6,8-dimethoxy-3a-(4-methoxyphenyl)-n,n-dimethyl-3-phenyl-2,3-dihydro-1h-cyclopenta[b][1]benzofuran-2-carboxamide
BRD-K97248244-001-02-6
BRD-K97248244-001-01-8
1h-cyclopenta(b)benzofuran-2-carboxamide, 2,3,3a,8b-tetrahydro-1,8b-dihydroxy-6,8-dimethoxy-3a-(4-methoxyphenyl)-n,n-dimethyl-3-phenyl-, (1r,2r,3s,3ar,8bs)-
frg4n852f7 ,
(-)-(1alpha,2alpha,3beta,3abeta,8bbeta)-2,3,3a,8b-tetrahydro-1,8b-dihydroxy-6,8-dimethoxy-3a-(4-methoxyphenyl)-n,n-dimethyl-3-phenyl-1h-cyclopenta(b)benzofuran-2-carboxamide
(1r,2r,3s,3ar,8bs)-1,8b-dihydroxy-6,8-dimethoxy-3a-(4-methoxyphenyl)-n,n-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1h-benzo[b]cyclopenta[d]furan-2-carboxamide
S7428
SCHEMBL752144
HY-19356
CS-5246
roc-a
1h-cyclopenta[b]benzofuran-2-carboxamide, 2,3,3a,8b-tetrahydro-1,8b-dihydroxy-6,8-dimethoxy-3a-(4-methoxyphenyl)-n,n-dimethyl-3-phenyl-, (1r,2r,3s,3ar,8bs)-
(1r,2r,3s,3ar,8bs)-1,8b-dihydroxy-6,8-dimethoxy-3a-(4-methoxyphenyl)-n,n-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1h-cyclopenta[b]benzofuran-2-carboxamide
'rocaglamide; rocaglamide a'
Q3437403
DB15495
117894-34-5
RCG ,
(1r,2r,3s,3ar,8bs)-6,8-dimethoxy-3a-(4-methoxyphenyl)-n,n-dimethyl-1,8b-bis(oxidanyl)-3-phenyl-2,3-dihydro-1h-cyclopenta[b][1]benzofuran-2-carboxamide
AT25539
DTXSID101004852
AS-79589
EX-A3220
AC-36727
(-)-rocaglamide

Excerpt	Reference	Relevance
"Rocaglamide-A (Roc-A) is a natural herbal medicine isolated from the genus Aglaia (family Meliaceae), which has a cyclopenta[b]benzofuran core structure."	( Inhibitory effects of Rocaglamide-A on PPARγ-driven adipogenesis through regulation of mitotic clonal expansion involving the JAK2/STAT3 pathway. Ha, YS; Hwang, S; Kim, J; Kim, SJ; Kim, TK; Park, KS, 2022)	1.76

Excerpt	Reference	Relevance
"Rocaglamide has been reported to sensitize several cell types to TRAIL-induced apoptosis. "	( Sensitization of renal carcinoma cells to TRAIL-induced apoptosis by rocaglamide and analogs. Brown, LE; Henrich, CJ; Nalli, AD; Porco, JA; Sayers, TJ; Thomas, CL, 2018)	2.16

Excerpt	Reference	Relevance
"Rocaglamides are able to suppress the PMA-induced expression of NF-kappaB target genes and sensitize leukemic T cells to apoptosis induced by TNFalpha, cisplatin, and gamma-irradiation."	( Rocaglamide derivatives are potent inhibitors of NF-kappa B activation in T-cells. Baumann, B; Bohnenstengel, F; Debatin, KM; Herr, I; Proksch, P; Siegmund, D; Wajant, H; Weber, C; Wirth, T, 2002)	2.48

Excerpt	Reference	Relevance
"Rocaglamide treatment further prevented the oncogenic growth of KRAS-driven lung cancer allografts and xenografts in mouse models."	( Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours. Binder, H; David, K; Désaubry, L; Marini, F; Rajalingam, K; Weber, C; Yurugi, H; Zhao, Q, 2017)	1.18

Role	Description
metabolite	Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
antileishmanial agent	An antiprotozoal drug used to treat or prevent infections caused by protozoan parasites that belong to the genus Leishmania.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
organic heterotricyclic compound	An organic tricyclic compound in which at least one of the rings of the tricyclic skeleton contains one or more heteroatoms.
monomethoxybenzene	Compounds containing a benzene skeleton substituted with one methoxy group.
monocarboxylic acid amide	A carboxamide derived from a monocarboxylic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
TDP1 protein	Homo sapiens (human)	Potency	0.0083	0.0008	11.3822	44.6684	AID686978; AID686979
67.9K protein	Vaccinia virus	Potency	0.0001	0.0001	8.4406	100.0000	AID720580
IDH1	Homo sapiens (human)	Potency	0.0065	0.0052	10.8652	35.4813	AID686970
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	0.0176	0.0041	9.9848	25.9290	AID504444; AID720524
geminin	Homo sapiens (human)	Potency	5.4852	0.0046	11.3741	33.4983	AID624296; AID624297
Glycoprotein hormones alpha chain	Homo sapiens (human)	Potency	2.5119	4.4668	8.3448	10.0000	AID624291
Alpha-synuclein	Homo sapiens (human)	Potency	10.0000	0.5623	9.3985	25.1189	AID652106
TAR DNA-binding protein 43	Homo sapiens (human)	Potency	31.6228	1.7783	16.2081	35.4813	AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)	IC50 (µMol)	1.0375	0.0001	1.9731	8.0000	AID468108; AID479074
Eukaryotic initiation factor 4A-I	Homo sapiens (human)	IC50 (µMol)	0.1044	0.0047	0.4064	3.1000	AID1656113; AID1656114; AID1656115; AID1656116
Transcription factor p65	Homo sapiens (human)	IC50 (µMol)	0.7367	0.0001	1.8981	8.8000	AID1398545; AID1538679; AID468110; AID479075; AID599230; AID606031
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Eukaryotic initiation factor 4A-I	Homo sapiens (human)	Kd	0.1560	0.1560	0.1560	0.1560	AID1656105
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)	ED50	2.0000	2.0000	2.0000	2.0000	AID471919
Transcription factor p65	Homo sapiens (human)	ED50	0.0800	0.0050	0.0425	0.0800	AID733967
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
G protein-coupled receptor signaling pathway	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of cell population proliferation	Glycoprotein hormones alpha chain	Homo sapiens (human)
hormone-mediated signaling pathway	Glycoprotein hormones alpha chain	Homo sapiens (human)
regulation of signaling receptor activity	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of steroid biosynthetic process	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of cell migration	Glycoprotein hormones alpha chain	Homo sapiens (human)
thyroid gland development	Glycoprotein hormones alpha chain	Homo sapiens (human)
luteinizing hormone secretion	Glycoprotein hormones alpha chain	Homo sapiens (human)
organ growth	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone signaling pathway	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Glycoprotein hormones alpha chain	Homo sapiens (human)
negative regulation of organ growth	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone secretion	Glycoprotein hormones alpha chain	Homo sapiens (human)
thyroid hormone generation	Glycoprotein hormones alpha chain	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to lipopolysaccharide	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
transcription by RNA polymerase II	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
apoptotic process	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
inflammatory response	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
canonical NF-kappaB signal transduction	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
JNK cascade	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of gene expression	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiation	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of lipid storage	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of calcidiol 1-monooxygenase activity	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of vitamin D biosynthetic process	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of cholesterol transport	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of interleukin-12 production	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
response to muscle stretch	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
non-canonical NF-kappaB signal transduction	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of apoptotic process	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of DNA-templated transcription	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of inflammatory response	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
B cell receptor signaling pathway	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of protein metabolic process	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
mammary gland involution	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of transcription initiation by RNA polymerase II	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to mechanical stimulus	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to nicotine	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to interleukin-1	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to interleukin-6	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to tumor necrosis factor	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to dsRNA	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to interleukin-17	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to virus	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
antibacterial innate immune response	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of hyaluronan biosynthetic process	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to angiotensin	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of miRNA metabolic process	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to stress	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
innate immune response	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
response to cytokine	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
calcium ion homeostasis	Alpha-synuclein	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Alpha-synuclein	Homo sapiens (human)
microglial cell activation	Alpha-synuclein	Homo sapiens (human)
positive regulation of receptor recycling	Alpha-synuclein	Homo sapiens (human)
positive regulation of neurotransmitter secretion	Alpha-synuclein	Homo sapiens (human)
negative regulation of protein kinase activity	Alpha-synuclein	Homo sapiens (human)
fatty acid metabolic process	Alpha-synuclein	Homo sapiens (human)
neutral lipid metabolic process	Alpha-synuclein	Homo sapiens (human)
phospholipid metabolic process	Alpha-synuclein	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Alpha-synuclein	Homo sapiens (human)
mitochondrial membrane organization	Alpha-synuclein	Homo sapiens (human)
adult locomotory behavior	Alpha-synuclein	Homo sapiens (human)
response to xenobiotic stimulus	Alpha-synuclein	Homo sapiens (human)
response to iron(II) ion	Alpha-synuclein	Homo sapiens (human)
regulation of phospholipase activity	Alpha-synuclein	Homo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathway	Alpha-synuclein	Homo sapiens (human)
regulation of glutamate secretion	Alpha-synuclein	Homo sapiens (human)
regulation of dopamine secretion	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle exocytosis	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle priming	Alpha-synuclein	Homo sapiens (human)
regulation of transmembrane transporter activity	Alpha-synuclein	Homo sapiens (human)
negative regulation of microtubule polymerization	Alpha-synuclein	Homo sapiens (human)
receptor internalization	Alpha-synuclein	Homo sapiens (human)
protein destabilization	Alpha-synuclein	Homo sapiens (human)
response to magnesium ion	Alpha-synuclein	Homo sapiens (human)
negative regulation of transporter activity	Alpha-synuclein	Homo sapiens (human)
response to lipopolysaccharide	Alpha-synuclein	Homo sapiens (human)
negative regulation of monooxygenase activity	Alpha-synuclein	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Alpha-synuclein	Homo sapiens (human)
response to type II interferon	Alpha-synuclein	Homo sapiens (human)
cellular response to oxidative stress	Alpha-synuclein	Homo sapiens (human)
SNARE complex assembly	Alpha-synuclein	Homo sapiens (human)
positive regulation of SNARE complex assembly	Alpha-synuclein	Homo sapiens (human)
regulation of locomotion	Alpha-synuclein	Homo sapiens (human)
dopamine biosynthetic process	Alpha-synuclein	Homo sapiens (human)
mitochondrial ATP synthesis coupled electron transport	Alpha-synuclein	Homo sapiens (human)
regulation of macrophage activation	Alpha-synuclein	Homo sapiens (human)
positive regulation of apoptotic process	Alpha-synuclein	Homo sapiens (human)
negative regulation of apoptotic process	Alpha-synuclein	Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	Alpha-synuclein	Homo sapiens (human)
negative regulation of neuron apoptotic process	Alpha-synuclein	Homo sapiens (human)
positive regulation of endocytosis	Alpha-synuclein	Homo sapiens (human)
negative regulation of exocytosis	Alpha-synuclein	Homo sapiens (human)
positive regulation of exocytosis	Alpha-synuclein	Homo sapiens (human)
regulation of long-term neuronal synaptic plasticity	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle endocytosis	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle transport	Alpha-synuclein	Homo sapiens (human)
positive regulation of inflammatory response	Alpha-synuclein	Homo sapiens (human)
regulation of acyl-CoA biosynthetic process	Alpha-synuclein	Homo sapiens (human)
protein tetramerization	Alpha-synuclein	Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosol	Alpha-synuclein	Homo sapiens (human)
neuron apoptotic process	Alpha-synuclein	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	Alpha-synuclein	Homo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmission	Alpha-synuclein	Homo sapiens (human)
negative regulation of serotonin uptake	Alpha-synuclein	Homo sapiens (human)
regulation of norepinephrine uptake	Alpha-synuclein	Homo sapiens (human)
negative regulation of norepinephrine uptake	Alpha-synuclein	Homo sapiens (human)
excitatory postsynaptic potential	Alpha-synuclein	Homo sapiens (human)
long-term synaptic potentiation	Alpha-synuclein	Homo sapiens (human)
positive regulation of inositol phosphate biosynthetic process	Alpha-synuclein	Homo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathway	Alpha-synuclein	Homo sapiens (human)
response to interleukin-1	Alpha-synuclein	Homo sapiens (human)
cellular response to copper ion	Alpha-synuclein	Homo sapiens (human)
cellular response to epinephrine stimulus	Alpha-synuclein	Homo sapiens (human)
positive regulation of protein serine/threonine kinase activity	Alpha-synuclein	Homo sapiens (human)
supramolecular fiber organization	Alpha-synuclein	Homo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinone	Alpha-synuclein	Homo sapiens (human)
positive regulation of glutathione peroxidase activity	Alpha-synuclein	Homo sapiens (human)
positive regulation of hydrogen peroxide catabolic process	Alpha-synuclein	Homo sapiens (human)
regulation of synaptic vesicle recycling	Alpha-synuclein	Homo sapiens (human)
regulation of reactive oxygen species biosynthetic process	Alpha-synuclein	Homo sapiens (human)
positive regulation of protein localization to cell periphery	Alpha-synuclein	Homo sapiens (human)
negative regulation of chaperone-mediated autophagy	Alpha-synuclein	Homo sapiens (human)
regulation of presynapse assembly	Alpha-synuclein	Homo sapiens (human)
amyloid fibril formation	Alpha-synuclein	Homo sapiens (human)
synapse organization	Alpha-synuclein	Homo sapiens (human)
chemical synaptic transmission	Alpha-synuclein	Homo sapiens (human)
cytoplasmic translational initiation	Eukaryotic initiation factor 4A-I	Homo sapiens (human)
translational initiation	Eukaryotic initiation factor 4A-I	Homo sapiens (human)
positive regulation of interleukin-1 beta production	Transcription factor p65	Homo sapiens (human)
positive regulation of interleukin-6 production	Transcription factor p65	Homo sapiens (human)
positive regulation of interleukin-8 production	Transcription factor p65	Homo sapiens (human)
positive regulation of amyloid-beta formation	Transcription factor p65	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Transcription factor p65	Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathway	Transcription factor p65	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Transcription factor p65	Homo sapiens (human)
liver development	Transcription factor p65	Homo sapiens (human)
hair follicle development	Transcription factor p65	Homo sapiens (human)
defense response to tumor cell	Transcription factor p65	Homo sapiens (human)
response to ischemia	Transcription factor p65	Homo sapiens (human)
acetaldehyde metabolic process	Transcription factor p65	Homo sapiens (human)
chromatin organization	Transcription factor p65	Homo sapiens (human)
DNA-templated transcription	Transcription factor p65	Homo sapiens (human)
regulation of DNA-templated transcription	Transcription factor p65	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Transcription factor p65	Homo sapiens (human)
inflammatory response	Transcription factor p65	Homo sapiens (human)
cellular defense response	Transcription factor p65	Homo sapiens (human)
neuropeptide signaling pathway	Transcription factor p65	Homo sapiens (human)
canonical NF-kappaB signal transduction	Transcription factor p65	Homo sapiens (human)
positive regulation of cell population proliferation	Transcription factor p65	Homo sapiens (human)
response to xenobiotic stimulus	Transcription factor p65	Homo sapiens (human)
animal organ morphogenesis	Transcription factor p65	Homo sapiens (human)
response to UV-B	Transcription factor p65	Homo sapiens (human)
positive regulation of vascular endothelial growth factor production	Transcription factor p65	Homo sapiens (human)
positive regulation of gene expression	Transcription factor p65	Homo sapiens (human)
positive regulation of Schwann cell differentiation	Transcription factor p65	Homo sapiens (human)
negative regulation of angiogenesis	Transcription factor p65	Homo sapiens (human)
cytokine-mediated signaling pathway	Transcription factor p65	Homo sapiens (human)
protein catabolic process	Transcription factor p65	Homo sapiens (human)
response to muramyl dipeptide	Transcription factor p65	Homo sapiens (human)
response to progesterone	Transcription factor p65	Homo sapiens (human)
positive regulation of interleukin-12 production	Transcription factor p65	Homo sapiens (human)
positive regulation of interleukin-6 production	Transcription factor p65	Homo sapiens (human)
positive regulation of interleukin-8 production	Transcription factor p65	Homo sapiens (human)
response to insulin	Transcription factor p65	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Transcription factor p65	Homo sapiens (human)
negative regulation of protein sumoylation	Transcription factor p65	Homo sapiens (human)
response to cobalamin	Transcription factor p65	Homo sapiens (human)
toll-like receptor 4 signaling pathway	Transcription factor p65	Homo sapiens (human)
intracellular signal transduction	Transcription factor p65	Homo sapiens (human)
cellular response to hepatocyte growth factor stimulus	Transcription factor p65	Homo sapiens (human)
response to muscle stretch	Transcription factor p65	Homo sapiens (human)
non-canonical NF-kappaB signal transduction	Transcription factor p65	Homo sapiens (human)
vascular endothelial growth factor signaling pathway	Transcription factor p65	Homo sapiens (human)
prolactin signaling pathway	Transcription factor p65	Homo sapiens (human)
negative regulation of protein catabolic process	Transcription factor p65	Homo sapiens (human)
negative regulation of apoptotic process	Transcription factor p65	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Transcription factor p65	Homo sapiens (human)
response to amino acid	Transcription factor p65	Homo sapiens (human)
negative regulation of DNA-templated transcription	Transcription factor p65	Homo sapiens (human)
positive regulation of DNA-templated transcription	Transcription factor p65	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Transcription factor p65	Homo sapiens (human)
negative regulation of insulin receptor signaling pathway	Transcription factor p65	Homo sapiens (human)
regulation of inflammatory response	Transcription factor p65	Homo sapiens (human)
positive regulation of T cell receptor signaling pathway	Transcription factor p65	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Transcription factor p65	Homo sapiens (human)
response to cAMP	Transcription factor p65	Homo sapiens (human)
defense response to virus	Transcription factor p65	Homo sapiens (human)
cellular response to hydrogen peroxide	Transcription factor p65	Homo sapiens (human)
interleukin-1-mediated signaling pathway	Transcription factor p65	Homo sapiens (human)
response to interleukin-1	Transcription factor p65	Homo sapiens (human)
cellular response to lipopolysaccharide	Transcription factor p65	Homo sapiens (human)
cellular response to lipoteichoic acid	Transcription factor p65	Homo sapiens (human)
cellular response to peptidoglycan	Transcription factor p65	Homo sapiens (human)
cellular response to nicotine	Transcription factor p65	Homo sapiens (human)
cellular response to interleukin-1	Transcription factor p65	Homo sapiens (human)
cellular response to interleukin-6	Transcription factor p65	Homo sapiens (human)
cellular response to tumor necrosis factor	Transcription factor p65	Homo sapiens (human)
postsynapse to nucleus signaling pathway	Transcription factor p65	Homo sapiens (human)
antiviral innate immune response	Transcription factor p65	Homo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transduction	Transcription factor p65	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	Transcription factor p65	Homo sapiens (human)
negative regulation of miRNA transcription	Transcription factor p65	Homo sapiens (human)
positive regulation of miRNA transcription	Transcription factor p65	Homo sapiens (human)
cellular response to angiotensin	Transcription factor p65	Homo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cell	Transcription factor p65	Homo sapiens (human)
positive regulation of miRNA metabolic process	Transcription factor p65	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway	Transcription factor p65	Homo sapiens (human)
cellular response to stress	Transcription factor p65	Homo sapiens (human)
response to cytokine	Transcription factor p65	Homo sapiens (human)
innate immune response	Transcription factor p65	Homo sapiens (human)
negative regulation of protein phosphorylation	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA processing	TAR DNA-binding protein 43	Homo sapiens (human)
RNA splicing	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of protein stability	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of insulin secretion	TAR DNA-binding protein 43	Homo sapiens (human)
response to endoplasmic reticulum stress	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of protein import into nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of circadian rhythm	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of apoptotic process	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation by host of viral transcription	TAR DNA-binding protein 43	Homo sapiens (human)
rhythmic process	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of cell cycle	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA destabilization	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA stabilization	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear inner membrane organization	TAR DNA-binding protein 43	Homo sapiens (human)
amyloid fibril formation	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
hormone activity	Glycoprotein hormones alpha chain	Homo sapiens (human)
protein binding	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone activity	Glycoprotein hormones alpha chain	Homo sapiens (human)
transcription cis-regulatory region binding	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
chromatin binding	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
DNA-binding transcription factor activity	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
transcription coregulator activity	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
protein binding	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
identical protein binding	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
actinin binding	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
fatty acid binding	Alpha-synuclein	Homo sapiens (human)
phospholipase D inhibitor activity	Alpha-synuclein	Homo sapiens (human)
SNARE binding	Alpha-synuclein	Homo sapiens (human)
magnesium ion binding	Alpha-synuclein	Homo sapiens (human)
transcription cis-regulatory region binding	Alpha-synuclein	Homo sapiens (human)
actin binding	Alpha-synuclein	Homo sapiens (human)
protein kinase inhibitor activity	Alpha-synuclein	Homo sapiens (human)
copper ion binding	Alpha-synuclein	Homo sapiens (human)
calcium ion binding	Alpha-synuclein	Homo sapiens (human)
protein binding	Alpha-synuclein	Homo sapiens (human)
phospholipid binding	Alpha-synuclein	Homo sapiens (human)
ferrous iron binding	Alpha-synuclein	Homo sapiens (human)
zinc ion binding	Alpha-synuclein	Homo sapiens (human)
lipid binding	Alpha-synuclein	Homo sapiens (human)
oxidoreductase activity	Alpha-synuclein	Homo sapiens (human)
kinesin binding	Alpha-synuclein	Homo sapiens (human)
Hsp70 protein binding	Alpha-synuclein	Homo sapiens (human)
histone binding	Alpha-synuclein	Homo sapiens (human)
identical protein binding	Alpha-synuclein	Homo sapiens (human)
alpha-tubulin binding	Alpha-synuclein	Homo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic process	Alpha-synuclein	Homo sapiens (human)
tau protein binding	Alpha-synuclein	Homo sapiens (human)
phosphoprotein binding	Alpha-synuclein	Homo sapiens (human)
molecular adaptor activity	Alpha-synuclein	Homo sapiens (human)
dynein complex binding	Alpha-synuclein	Homo sapiens (human)
cuprous ion binding	Alpha-synuclein	Homo sapiens (human)
RNA cap binding	Eukaryotic initiation factor 4A-I	Homo sapiens (human)
RNA binding	Eukaryotic initiation factor 4A-I	Homo sapiens (human)
RNA helicase activity	Eukaryotic initiation factor 4A-I	Homo sapiens (human)
double-stranded RNA binding	Eukaryotic initiation factor 4A-I	Homo sapiens (human)
mRNA binding	Eukaryotic initiation factor 4A-I	Homo sapiens (human)
translation initiation factor activity	Eukaryotic initiation factor 4A-I	Homo sapiens (human)
helicase activity	Eukaryotic initiation factor 4A-I	Homo sapiens (human)
protein binding	Eukaryotic initiation factor 4A-I	Homo sapiens (human)
ATP binding	Eukaryotic initiation factor 4A-I	Homo sapiens (human)
translation factor activity, RNA binding	Eukaryotic initiation factor 4A-I	Homo sapiens (human)
ATP hydrolysis activity	Eukaryotic initiation factor 4A-I	Homo sapiens (human)
transcription cis-regulatory region binding	Transcription factor p65	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Transcription factor p65	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Transcription factor p65	Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA binding	Transcription factor p65	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Transcription factor p65	Homo sapiens (human)
transcription coactivator binding	Transcription factor p65	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Transcription factor p65	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Transcription factor p65	Homo sapiens (human)
DNA binding	Transcription factor p65	Homo sapiens (human)
chromatin binding	Transcription factor p65	Homo sapiens (human)
DNA-binding transcription factor activity	Transcription factor p65	Homo sapiens (human)
protein binding	Transcription factor p65	Homo sapiens (human)
enzyme binding	Transcription factor p65	Homo sapiens (human)
protein kinase binding	Transcription factor p65	Homo sapiens (human)
chromatin DNA binding	Transcription factor p65	Homo sapiens (human)
ubiquitin protein ligase binding	Transcription factor p65	Homo sapiens (human)
peptide binding	Transcription factor p65	Homo sapiens (human)
phosphate ion binding	Transcription factor p65	Homo sapiens (human)
identical protein binding	Transcription factor p65	Homo sapiens (human)
protein homodimerization activity	Transcription factor p65	Homo sapiens (human)
actinin binding	Transcription factor p65	Homo sapiens (human)
histone deacetylase binding	Transcription factor p65	Homo sapiens (human)
NF-kappaB binding	Transcription factor p65	Homo sapiens (human)
ankyrin repeat binding	Transcription factor p65	Homo sapiens (human)
general transcription initiation factor binding	Transcription factor p65	Homo sapiens (human)
DNA-binding transcription factor binding	Transcription factor p65	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
double-stranded DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
RNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA 3'-UTR binding	TAR DNA-binding protein 43	Homo sapiens (human)
protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
lipid binding	TAR DNA-binding protein 43	Homo sapiens (human)
identical protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
pre-mRNA intronic binding	TAR DNA-binding protein 43	Homo sapiens (human)
molecular condensate scaffold activity	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular region	Glycoprotein hormones alpha chain	Homo sapiens (human)
extracellular space	Glycoprotein hormones alpha chain	Homo sapiens (human)
Golgi lumen	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone complex	Glycoprotein hormones alpha chain	Homo sapiens (human)
pituitary gonadotropin complex	Glycoprotein hormones alpha chain	Homo sapiens (human)
extracellular space	Glycoprotein hormones alpha chain	Homo sapiens (human)
extracellular region	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
nucleus	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
nucleoplasm	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cytoplasm	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
mitochondrion	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cytosol	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
secretory granule lumen	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
specific granule lumen	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
chromatin	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
transcription regulator complex	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
I-kappaB/NF-kappaB complex	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
nucleus	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cytoplasm	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
NF-kappaB p50/p65 complex	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
platelet alpha granule membrane	Alpha-synuclein	Homo sapiens (human)
extracellular region	Alpha-synuclein	Homo sapiens (human)
extracellular space	Alpha-synuclein	Homo sapiens (human)
nucleus	Alpha-synuclein	Homo sapiens (human)
cytoplasm	Alpha-synuclein	Homo sapiens (human)
mitochondrion	Alpha-synuclein	Homo sapiens (human)
lysosome	Alpha-synuclein	Homo sapiens (human)
cytosol	Alpha-synuclein	Homo sapiens (human)
plasma membrane	Alpha-synuclein	Homo sapiens (human)
cell cortex	Alpha-synuclein	Homo sapiens (human)
actin cytoskeleton	Alpha-synuclein	Homo sapiens (human)
membrane	Alpha-synuclein	Homo sapiens (human)
inclusion body	Alpha-synuclein	Homo sapiens (human)
axon	Alpha-synuclein	Homo sapiens (human)
growth cone	Alpha-synuclein	Homo sapiens (human)
synaptic vesicle membrane	Alpha-synuclein	Homo sapiens (human)
perinuclear region of cytoplasm	Alpha-synuclein	Homo sapiens (human)
postsynapse	Alpha-synuclein	Homo sapiens (human)
supramolecular fiber	Alpha-synuclein	Homo sapiens (human)
protein-containing complex	Alpha-synuclein	Homo sapiens (human)
cytoplasm	Alpha-synuclein	Homo sapiens (human)
axon terminus	Alpha-synuclein	Homo sapiens (human)
neuronal cell body	Alpha-synuclein	Homo sapiens (human)
nucleus	Eukaryotic initiation factor 4A-I	Homo sapiens (human)
cytoplasm	Eukaryotic initiation factor 4A-I	Homo sapiens (human)
cytosol	Eukaryotic initiation factor 4A-I	Homo sapiens (human)
membrane	Eukaryotic initiation factor 4A-I	Homo sapiens (human)
eukaryotic translation initiation factor 4F complex	Eukaryotic initiation factor 4A-I	Homo sapiens (human)
extracellular exosome	Eukaryotic initiation factor 4A-I	Homo sapiens (human)
nucleolus	Transcription factor p65	Homo sapiens (human)
nucleus	Transcription factor p65	Homo sapiens (human)
glutamatergic synapse	Transcription factor p65	Homo sapiens (human)
nucleus	Transcription factor p65	Homo sapiens (human)
nucleoplasm	Transcription factor p65	Homo sapiens (human)
cytoplasm	Transcription factor p65	Homo sapiens (human)
cytosol	Transcription factor p65	Homo sapiens (human)
NF-kappaB p50/p65 complex	Transcription factor p65	Homo sapiens (human)
NF-kappaB complex	Transcription factor p65	Homo sapiens (human)
chromatin	Transcription factor p65	Homo sapiens (human)
transcription regulator complex	Transcription factor p65	Homo sapiens (human)
cytoplasm	Transcription factor p65	Homo sapiens (human)
intracellular non-membrane-bounded organelle	TAR DNA-binding protein 43	Homo sapiens (human)
nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
perichromatin fibrils	TAR DNA-binding protein 43	Homo sapiens (human)
mitochondrion	TAR DNA-binding protein 43	Homo sapiens (human)
cytoplasmic stress granule	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear speck	TAR DNA-binding protein 43	Homo sapiens (human)
interchromatin granule	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
chromatin	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (51)

Assay ID	Title	Year	Journal	Article
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID398901	Cytotoxicity against human A549 cells	1997	Journal of natural products, Jun, Volume: 60, Issue:6	Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia.
AID1100803	Antifungal activity against Fusarium avenaceum VIAM MA1512 assessed as inhibition of spore germination by microdilution technique linked with digital image analysis	2000	Journal of agricultural and food chemistry, Apr, Volume: 48, Issue:4	Cyclopenta[b]benzofurans from Aglaia species with pronounced antifungal activity against rice blast fungus (Pyricularia grisea).
AID1100805	Antifungal activity against Magnaporthe grisea VIAM MA1627 assessed as inhibition of spore germination by microdilution technique linked with digital image analysis	2000	Journal of agricultural and food chemistry, Apr, Volume: 48, Issue:4	Cyclopenta[b]benzofurans from Aglaia species with pronounced antifungal activity against rice blast fungus (Pyricularia grisea).
AID471919	Inhibition of NF kappaB p50 subunit signaling pathway in human HeLa cells by biotinylated-ELISA	2009	Journal of natural products, Jun, Volume: 72, Issue:6	Bioactive 5,6-dihydro-alpha-pyrone derivatives from Hyptis brevipes.
AID292727	Inhibition of NF-kappaB by ELISA assay	2007	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1	Ponapensin, a cyclopenta[bc]benzopyran with potent NF-kappaB inhibitory activity from Aglaia ponapensis.
AID1656105	Binding affinity to full length recombinant eIF4A1 (unknown origin) assessed as induction ternary complex formation in presence of AGAGAG by measuring Kd for AGAGAG + ATP complex formation SPR assay (Rvb = 8 +/- 0.9 microM)	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase.
AID1656115	Inhibition of eIF4A1 in human MDA-MB-231 cells assessed as inhibition of cellular-translation incubated for 4 hrs by specific tandem sequence motif repeat CCGCCG in 5'- UTR containing luciferase reporter gene assay	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase.
AID398905	Cytotoxicity against human TE671 cells	1997	Journal of natural products, Jun, Volume: 60, Issue:6	Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia.
AID398895	In vivo cytotoxic activity against mouse P388 cells at 1 mg/kg relative to control	1997	Journal of natural products, Jun, Volume: 60, Issue:6	Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia.
AID1100804	Antifungal activity against Alternaria citri CBS 192.81; VIAM MA1628 assessed as inhibition of spore germination by microdilution technique linked with digital image analysis	2000	Journal of agricultural and food chemistry, Apr, Volume: 48, Issue:4	Cyclopenta[b]benzofurans from Aglaia species with pronounced antifungal activity against rice blast fungus (Pyricularia grisea).
AID1272158	Binding affinity to eIF4A2 in mouse embryonic fibroblasts at 20 uM by streptavidin pulldown assay	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Total synthesis of a biotinylated rocaglate: Selective targeting of the translation factors eIF4AI/II.
AID1398545	Inhibition of biotinylated consensus sequence binding to NF-kB p65 in human HeLa nuclear extracts after 3 hrs by ELISA	2018	Bioorganic & medicinal chemistry, 08-15, Volume: 26, Issue:15	Cytotoxic and NF-κB and mitochondrial transmembrane potential inhibitory pentacyclic triterpenoids from Syzygium corticosum and their semi-synthetic derivatives.
AID1295996	Cytotoxicity against human NCI-H929 cells after 48 hrs by MTS assay	2016	Journal of natural products, Feb-26, Volume: 79, Issue:2	Dysiherbols A-C and Dysideanone E, Cytotoxic and NF-κB Inhibitory Tetracyclic Meroterpenes from a Dysidea sp. Marine Sponge.
AID606031	Inhibition of NFkappa p65 isolated from nuclear extract of human HeLa cells by ELISA	2011	Journal of natural products, May-27, Volume: 74, Issue:5	Resorcylic acid lactones with cytotoxic and NF-κB inhibitory activities and their structure-activity relationships.
AID733969	Cytotoxicity against human HT-29 cells	2013	Journal of natural products, Mar-22, Volume: 76, Issue:3	Bioactive flavaglines and other constituents isolated from Aglaia perviridis.
AID1656116	Inhibition of eIF4A1 in human MDA-MB-231 cells assessed as inhibition of cellular-translation incubated for 4 hrs by specific tandem sequence motif repeat CAACAA in 5'- UTR containing luciferase reporter gene assay	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase.
AID733968	Cytotoxicity against human CCD-112CoN cells	2013	Journal of natural products, Mar-22, Volume: 76, Issue:3	Bioactive flavaglines and other constituents isolated from Aglaia perviridis.
AID398902	Cytotoxicity against human HCT8 cells	1997	Journal of natural products, Jun, Volume: 60, Issue:6	Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia.
AID1295995	Inhibition of TNF alpha-induced NF-kappaB (unknown origin) activation in HEK293 cells after 6 hrs by luciferase reporter gene assay	2016	Journal of natural products, Feb-26, Volume: 79, Issue:2	Dysiherbols A-C and Dysideanone E, Cytotoxic and NF-κB Inhibitory Tetracyclic Meroterpenes from a Dysidea sp. Marine Sponge.
AID468110	Inhibition of nuclear factor NF-kappa-B p65 subunit after 1 hr by ELISA	2009	Journal of natural products, Nov, Volume: 72, Issue:11	Cytotoxic xanthone constituents of the stem bark of Garcinia mangostana (mangosteen).
AID398896	Antiplatelet aggregation activity against ADP-induced rabbit platelet assessed as platelet aggregation at 100 ug/mL relative to control	1997	Journal of natural products, Jun, Volume: 60, Issue:6	Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia.
AID398899	Antiplatelet aggregation activity against collagen-induced rabbit platelet assessed as platelet aggregation at 100 ug/mL relative to control	1997	Journal of natural products, Jun, Volume: 60, Issue:6	Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia.
AID398903	Cytotoxicity against mouse P388 cells	1997	Journal of natural products, Jun, Volume: 60, Issue:6	Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia.
AID599230	Inhibition of NFkappa p65 in nuclear extract of human HeLa cells assessed as blockade of NFkappa p65 binding to biotinylated-consesus sequence by ELISA	2011	Journal of natural products, May-27, Volume: 74, Issue:5	Cytotoxic and NF-κB inhibitory constituents of the stems of Cratoxylum cochinchinense and their semisynthetic analogues.
AID398898	Antiplatelet aggregation activity against platelet activating factor-induced rabbit platelet assessed as platelet aggregation at 100 ug/mL relative to control	1997	Journal of natural products, Jun, Volume: 60, Issue:6	Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia.
AID1656113	Inhibition of eIF4A1 in human MDA-MB-231 cells assessed as inhibition of cellular-translation incubated for 4 hrs by specific tandem sequence motif repeat AGAGAG in 5'- UTR containing luciferase reporter gene assay	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase.
AID1656114	Inhibition of eIF4A1 in human MDA-MB-231 cells assessed as inhibition of cellular-translation incubated for 4 hrs by specific tandem sequence motif repeat GGCGGC in 5'- UTR containing luciferase reporter gene assay	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase.
AID479075	Inhibition of NFkappa p65 isolated from nuclear extract of human HeLa cells assessed as blockade of binding to biotinylated consesus sequence by chemiluminescence assay	2010	Journal of natural products, May-28, Volume: 73, Issue:5	Cytotoxic and NF-kappaB inhibitory constituents of Artocarpus rigida.
AID733967	Inhibition of NF-kappaB p65 (unknown origin) by ELISA	2013	Journal of natural products, Mar-22, Volume: 76, Issue:3	Bioactive flavaglines and other constituents isolated from Aglaia perviridis.
AID479074	Inhibition of NFkappa p50 isolated from nuclear extract of human HeLa cells assessed as blockade of binding to biotinylated consesus sequence by chemiluminescence assay	2010	Journal of natural products, May-28, Volume: 73, Issue:5	Cytotoxic and NF-kappaB inhibitory constituents of Artocarpus rigida.
AID398897	Antiplatelet aggregation activity against arachidonic acid-induced rabbit platelet assessed as platelet aggregation at 100 ug/mL relative to control	1997	Journal of natural products, Jun, Volume: 60, Issue:6	Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia.
AID1538679	Inhibition of TNF alpha stimulated NF-KappaB p65 in human HeLa nuclear extract assessed as decrease in NF-KappaB translocation to nucleus measured after 5 hrs by ELISA	2019	Journal of natural products, 06-28, Volume: 82, Issue:6	Caspase-Dependent Apoptosis in Prostate Cancer Cells and Zebrafish by Corchorusoside C from Streptocaulon juventas.
AID1656093	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell proliferation incubated for 72 hrs by CellTiter-Glo reagent based assay	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase.
AID398900	Cytotoxicity against human KB cells	1997	Journal of natural products, Jun, Volume: 60, Issue:6	Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia.
AID1272157	Binding affinity to eIF4A1 in mouse embryonic fibroblasts at 20 uM by streptavidin pulldown assay	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Total synthesis of a biotinylated rocaglate: Selective targeting of the translation factors eIF4AI/II.
AID398904	Cytotoxicity against human RPMI7951 cells	1997	Journal of natural products, Jun, Volume: 60, Issue:6	Cytotoxic and antiplatelet aggregation principles from Aglaia elliptifolia.
AID468108	Inhibition of p50 after 1 hr by ELISA	2009	Journal of natural products, Nov, Volume: 72, Issue:11	Cytotoxic xanthone constituents of the stem bark of Garcinia mangostana (mangosteen).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	2 (2.44)	18.2507
2000's	19 (23.17)	29.6817
2010's	43 (52.44)	24.3611
2020's	18 (21.95)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	3 (3.57%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	81 (96.43%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
putrescine [no description available]	7	1	alkane-alpha,omega-diamine	antioxidant; fundamental metabolite
ellipticine ellipticine : A organic heterotetracyclic compound that is pyrido[4,3-b]carbazole carrying two methyl substituents at positions 5 and 11.	2.21	1	indole alkaloid; organic heterotetracyclic compound; organonitrogen heterocyclic compound; polycyclic heteroarene	antineoplastic agent; plant metabolite
hypericin [no description available]	2.07	1
mitomycin Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.	7.6	1	mitomycin	alkylating agent; antineoplastic agent
penicillin g Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.	2.06	1	penicillin allergen; penicillin	antibacterial drug; drug allergen; epitope
cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.	2.63	2	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	2.11	1	pyrrole; secondary amine
syringaldehyde syringaldehyde: isolated from nonfermented fiber fractions of oat hulls and cottonseed hulls. syringaldehyde : A hydroxybenzaldehyde that is 4-hydroxybenzaldehyde substituted by methoxy groups at positions 3 and 5. Isolated from Pisonia aculeata and Panax japonicus var. major, it exhibits hypoglycemic activity.	2.17	1	dimethoxybenzene; hydroxybenzaldehyde	hypoglycemic agent; plant metabolite
perylene Perylene: A 20-carbon dibenz(de,kl)anthracene that can be viewed as a naphthalene fused to a phenalene or as dinaphthalene. It is used as fluorescent lipid probe in the cytochemistry of membranes and is a polycyclic hydrocarbon pollutant in soil and water. Derivatives may be carcinogenic.. perylene : An ortho- and peri-fused polycyclic arene comprising of five benzene rings that is anthracene in which the d,e and k,l sides are fused to benzene rings.	2.07	1	ortho- and peri-fused polycyclic arene; perylenes
cyclopentane Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.	2.44	2	cycloalkane; cyclopentanes; volatile organic compound	non-polar solvent
thiazoles [no description available]	2.07	1	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
ketene ketene: structure. ketene : Carbonyl compounds where the C=O bond is conjugated to an alkylidene group.	7.04	1	ketene
oleanolic acid [no description available]	2.17	1	hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
3-hydroxyflavone 3-hydroxyflavone: structure given in first source. flavonol : A monohydroxyflavone that is the 3-hydroxy derivative of flavone.	7.46	2	flavonols; monohydroxyflavone
palladium Palladium: A chemical element having an atomic weight of 106.4, atomic number of 46, and the symbol Pd. It is a white, ductile metal resembling platinum, and following it in abundance and importance of applications. It is used in dentistry in the form of gold, silver, and copper alloys.. palladium : Chemical element (nickel group element atom) with atomic number 46.	7.52	2	metal allergen; nickel group element atom; platinum group metal atom
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	2.46	2	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
tetradecanoylphorbol acetate Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.	2.01	1	acetate ester; diester; phorbol ester; tertiary alpha-hydroxy ketone; tetradecanoate ester	antineoplastic agent; apoptosis inducer; carcinogenic agent; mitogen; plant metabolite; protein kinase C agonist; reactive oxygen species generator
benomyl [no description available]	2	1	aromatic amide; benzimidazole fungicide; benzimidazoles; benzimidazolylcarbamate fungicide; carbamate ester	acaricide; anthelminthic drug; antifungal agrochemical; microtubule-destabilising agent; tubulin modulator
adenylyl imidodiphosphate Adenylyl Imidodiphosphate: 5'-Adenylic acid, monoanhydride with imidodiphosphoric acid. An analog of ATP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It is a potent competitive inhibitor of soluble and membrane-bound mitochondrial ATPase and also inhibits ATP-dependent reactions of oxidative phosphorylation.	2.21	1	adenosine 5'-phosphate
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	3.2	5	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	1.99	1	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
staurosporine [no description available]	3.19	5	indolocarbazole alkaloid; organic heterooctacyclic compound	apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector
ursolic acid [no description available]	2.5	2	hydroxy monocarboxylic acid; pentacyclic triterpenoid	geroprotector; plant metabolite
betulinic acid [no description available]	2.5	2	hydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-HIV agent; anti-inflammatory agent; antimalarial; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; plant metabolite
taleranol taleranol: a metabolite of ZEARALENONE which is a non-steroidal estrogenic lactone used as an anabolic compound in animal feed; a stereoisomer of ZERANOL (alpha-zearalanol)	2.06	1	macrolide
avarol avarol: RN given refers to parent cpd; extract from Dysidea avara(sea sponge)	2.13	1
betulin betulin: isolated from various white birch bark (BETULA). betulin : A pentacyclic triterpenoid that is lupane having a double bond at position 20(29) as well as 3beta-hydroxy and 28-hydroxymethyl substituents.	2.17	1	diol; pentacyclic triterpenoid	analgesic; anti-inflammatory agent; antineoplastic agent; antiviral agent; metabolite
uvaol uvaol: from Vauquelinia corymbosa (Rosaceae)	2.17	1	triterpenoid	metabolite
loliolide loliolide: RN given refers to (6S-cis)-isomer	2.17	1	benzofurans	metabolite
erythrodiol [no description available]	2.17	1	diol; pentacyclic triterpenoid; primary alcohol; secondary alcohol	plant metabolite
Zearalanone [no description available]	2.06	1	macrolide; resorcinols
biotin vitamin B7 : Any member of a group of vitamers that belong to the chemical structural class called biotins that exhibit biological activity against vitamin B7 deficiency. Vitamin B7 deficiency is very rare in individuals who take a normal balanced diet. Foods rich in biotin are egg yolk, liver, cereals, vegetables (spinach, mushrooms) and rice. Symptoms associated with vitamin B7 deficiency include thinning hair, scaly skin rashes around eyes, nose and mouth, and brittle nails. The vitamers include biotin and its ionized and salt forms.	2.13	1	biotins; vitamin B7	coenzyme; cofactor; Escherichia coli metabolite; fundamental metabolite; human metabolite; mouse metabolite; nutraceutical; prosthetic group; Saccharomyces cerevisiae metabolite
benzofurans Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.	7.5	63
bortezomib [no description available]	2.05	1	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
8-deoxygartanin 8-deoxygartanin: a butyrylcholinesterase inhibitor; isolated from Garcinia mangostana; structure in first source	2.05	1	xanthones
aglafoline aglafoline: a platelet activating factor antagonist; structure given in first source; isolated from Aglaia elliptifolia. aglafolin : A heterotricyclic compound based on a 2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan framework substituted by hydroxy groups at positions C-1 and C-8b, a methoxycarbonyl group at C-2, a phenyl group at C-3, a 4-methoxyphenyl group at C-3a and methoxy groups at C-6 and C-8. A platelet aggregation inhibitor found in Aglaia elliptifolia and Aglaia odorata.	3.13	5	methyl ester; organic heterotricyclic compound	metabolite; platelet aggregation inhibitor
rocaglaol rocaglaol: a cytotoxic cyclopenta(b)benzofuran from the bark of Aglaia crassinervia; structure in first source	4.04	4
lignans Lignans: A class of dibenzylbutane derivatives which occurs in higher plants and in fluids (bile, serum, urine, etc.) in man and other animals. These compounds, which have a potential anti-cancer role, can be synthesized in vitro by human fecal flora. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)	2	1
doxorubicin hydrochloride [no description available]	1.99	1	anthracycline
e-z cinnamic acid cinnamic acid : A monocarboxylic acid that consists of acrylic acid bearing a phenyl substituent at the 3-position. It is found in Cinnamomum cassia.. trans-cinnamic acid : The E (trans) isomer of cinnamic acid	2.13	1	cinnamic acid	plant metabolite
glycosides [no description available]	7	1
sesquiterpenes [no description available]	2.25	1
dehydrovomifoliol dehydrovomifoliol: isolated from Litsea sessilis; structure in first source. (6S)-dehydrovomifoliol : A dehydrovomifoliol that has S-configuration at the chiral centre.. dehydrovomifoliol : A fenchane monoterpenoid that is substituted by methyl groups at positions 3, 5, and 5, and by both a hydroxy group and a 3-oxobut-1-en-1-yl group at position 4.	2.17	1	dehydrovomifoliol	plant metabolite
digoxin Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.	2.21	1	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
zeranol Zeranol: A non-steroidal estrogen analog.	2.06	1	macrolide
sideroxylin sideroxylin: from Hydrastis canadensis; structure in first source. sideroxylin : A monomethoxyflavone that is flavone substituted by a methoxy group at position 7, hydroxy groups at positions 5 and 4' and methyl groups at positions 6 and 8. It has been isolated from Hydrastis canadensis and Eucalyptus species.	2.17	1	dihydroxyflavone; monomethoxyflavone	plant metabolite
scopoletin [no description available]	2.43	2	hydroxycoumarin	plant growth regulator; plant metabolite
vomifoliol blumenol A: a phytotoxin isolated from Oryza sativa Awaakamai; structure in first source. vomifoliol : A fenchane monoterpenoid that is 3,5,5-trimethylcyclohex-2-en-1-one substituted by a hydroxy and a (1E)-3-hydroxybut-1-en-1-yl group at position 4.. (6S,9R)-vomifoliol : A (6S)-vomifoliol with a R configuration for the hydroxy group at position 9.	2.17	1	(6S)-vomifoliol	metabolite; phytotoxin
zearalenone Zearalenone: (S-(E))-3,4,5,6,8,10-Hexahydro-14,16-dihydroxy-3-methyl-1H-2-benzoxacyclotetradecin-1,7(8H)-dione. One of a group of compounds known under the general designation of resorcylic acid lactones. Cis, trans, dextro and levo forms have been isolated from the fungus Gibberella zeae (formerly Fusarium graminearum). They have estrogenic activity, cause toxicity in livestock as feed contaminant, and have been used as anabolic or estrogen substitutes.. zearalenone : A macrolide comprising a fourteen-membered lactone fused to 1,3-dihydroxybenzene; a potent estrogenic metabolite produced by some Giberella species.	2.06	1	macrolide; resorcinols	fungal metabolite; mycoestrogen
gartanin gartanin : A member of the class of xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1, 3, 5 and 8 and prenyl groups at positions 2 and 4.	2.05	1	polyphenol; xanthones	antineoplastic agent; plant metabolite
mangostin mangostin: xanthone from rind of Garcinia mangostana Linn. fruit. alpha-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3 and 6, a methoxy group at position 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antioxidant, antimicrobial and antitumour activities.	2.46	2	aromatic ether; phenols; xanthones	antimicrobial agent; antineoplastic agent; antioxidant; plant metabolite
3,3',4-o-trimethylellagic acid 3,7,8-tri-O-methylellagic acid: structure given in first source	2.17	1	tannin
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	2.1	1	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
vinblastine sulfate [no description available]	1.99	1
gamma-mangostin gamma-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3, 6 and 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antitumour activity.	2.06	1	phenols; xanthones	antineoplastic agent; plant metabolite; protein kinase inhibitor
beta-Mangostin [no description available]	2.05	1	xanthones
9-Hydroxycalabaxanthone [no description available]	2.05	1	xanthones
fr 148083 5Z-7-oxozeaenol : A macrolide that is the 7-oxo derivative of zeaenol (the 5Z stereoisomer). Isolated from Fungi, it exhibits cytotoxic, antibacterial and inhibitory activity against NF-kappaB.	2.06	1	aromatic ether; macrolide; phenols; secondary alcohol; secondary alpha-hydroxy ketone	antibacterial agent; antineoplastic agent; metabolite; NF-kappaB inhibitor
LL-Z1640-1 [no description available]	2.06	1	macrolide; resorcinols	metabolite
hypothemycin hypothemycin: a resorcylic acid lactone antibiotic; antifungal metabolite from Hypomyces trichothecoides. hypothemycin : A macrolide that is isolated from the cultured broth of Hypomyces subiculosus and shows antifungal activity and inhibits the growth of some human cancer cells.	2.06	1	aromatic ether; diol; enone; epoxide; macrolide; phenols; polyketide; secondary alpha-hydroxy ketone	antifungal agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; fungal metabolite
hippuristanol hippuristanol: from the gorgonian Isis hippuris	2.53	2
pateamine a pateamine A: a 19-membered macrolide; structure in first source; inhibits eukaryotic translation initiation. pateamine : A marine macrodiolide that is isolated from the sponge Mycale hentscheli and exhibits anticancer and antiviral properties	2.07	1	1,3-thiazoles; macrodiolide; olefinic compound; primary amino compound; tertiary amino compound	antineoplastic agent; antiviral agent; eukaryotic initiation factor 4F inhibitor; marine metabolite
rocagloic acid rocagloic acid: from leaves of Aglaia elliptifolia: structure in first source	2.47	2
Cycloartobiloxanthone cycloartobiloxanthone: a flavonoid isolated from stem bark of Artocarpus gomezianus; has antineoplastic properties	2.05	1	pyranoxanthones
5-methyl-2-(3-oxo-1,2,2-trimethylcyclopentyl)benzoquinone 5-methyl-2-(3-oxo-1,2,2-trimethylcyclopentyl)benzoquinone: Highly oxidized cuparene-type sesquiterpenes from a mycelial culture of Flammulina velutipes; structure in first source	2.25	1	sesquiterpenoid
episilvestrol episilvestrol: isolated from the fruit and twig of Aglaia silvestris; structure in first source. epi-silvestrol : An organic heterotricyclic compound that is a 5'''-epimer of silvestrol. Isolated from Aglaia silvestris, it exhibits antineoplastic activity.	2.13	1	dioxanes; ether; methyl ester; organic heterotricyclic compound	antineoplastic agent; metabolite
silvestrol silvestrol: isolated from the fruit and twig of Aglaia silvestris. silvestrol : An organic heterotricyclic compound that consists of a 2,3,3a,8b-tetrahydro-H-benzo[b]cyclopenta[d]furan framework substituted by hydroxy groups at positions C-1 and C-8b, a methoxycarbonyl group at C-2, a phenyl group at C-3, a 4-methoxyphenyl group at C-3a, a methoxy group at C-8 and a 1,4-dioxan-2-yloxy group at position C-6 which in turn is substituted by a methoxy group at position 3 and a 1,2-dihydroxyethyl group at position 6. Isolated from Aglaia silvestris, it exhibits antineoplastic activity.	4.95	10	dioxanes; ether; methyl ester; organic heterotricyclic compound	antineoplastic agent; metabolite
2alpha,3beta-dihydroxy-20(29)-lupen-28-oic acid alphitolic acid: from the aerial parts of Gouania longipetala; structure in first source. 2alpha,3beta-dihydroxy-20(29)-lupen-28-oic acid : A pentacyclic triterpenoid that is betulinic acid carrying an additional alpha-hydroxy group at position 2. It has been isolated from Breynia fruticosa.	2.17	1	dihydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
3-isomangostin 3-isomangostin: structure in first source	2.05	1	xanthones
glycoprotein e2, hepatitis c virus glycoprotein E2, Hepatitis C virus: RN refers to quasispecies 4E; amino acid sequence known; caution: HCV also stands for hog cholera virus	2.11	1
plx4032 [no description available]	2.15	1	aromatic ketone; difluorobenzene; monochlorobenzenes; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Cancer of Prostate [description not available]	2.21	1
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.21	1
Breast Cancer [description not available]	2.25	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.25	1
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	2.41	1
Colorectal Cancer [description not available]	7.6	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.6	1
Malignant Neurilemmoma [description not available]	2.25	1
B-Cell Chronic Lymphocytic Leukemia [description not available]	2.31	1
Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.	2.31	1
Carcinoma, Non-Small Cell Lung [description not available]	2.57	2
Cancer of Lung [description not available]	2.57	2
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.57	2
Lung Neoplasms Tumors or cancer of the LUNG.	2.57	2
Enterovirus Infections Diseases caused by ENTEROVIRUS.	2.17	1
Metastase [description not available]	2.17	1
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	2.17	1
Adenocarcinoma Of Kidney [description not available]	2.17	1
Cancer of Kidney [description not available]	2.17	1
Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.	2.17	1
Kidney Neoplasms Tumors or cancers of the KIDNEY.	2.17	1
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	2.08	1
Benign Neoplasms [description not available]	2.79	3
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.79	3
Leucocythaemia [description not available]	2.96	4
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	7.96	4
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.11	1
Hepatocellular Carcinoma [description not available]	7.11	1
Cancer of Liver [description not available]	2.11	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.11	1
Liver Neoplasms Tumors or cancer of the LIVER.	2.11	1
Rheumatoid Arthritis [description not available]	2.11	1
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	2.11	1
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted [description not available]	2.11	1
Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.	2.11	1
Malignant Melanoma [description not available]	2.15	1
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	2.15	1
Kahler Disease [description not available]	2.15	1
ATLL [description not available]	2.5	2
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	7.15	1
Leukemia-Lymphoma, Adult T-Cell Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.	2.5	2
Leukemia, Lymphocytic, T Cell [description not available]	2.43	2
Leukemia, T-Cell A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.	2.43	2
Granuloma, Hodgkin [description not available]	2.07	1
Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.	2.07	1
Germinoblastoma [description not available]	2.07	1
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	2.07	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.03	1
Acute Lymphoid Leukemia [description not available]	2.03	1
Granulocytic Leukemia [description not available]	2.03	1
Granulocytic Leukemia, Chronic [description not available]	2.03	1
Acute Disease Disease having a short and relatively severe course.	2.03	1
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	2.03	1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	2.03	1
Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.	2.03	1

rocaglamide

Description

Cross-References

Synonyms (41)

Research Excerpts

Overview

Effects

Actions

Treatment

Roles (3)

Drug Classes (3)

Protein Targets (11)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (204)

Molecular Functions (66)

Ceullar Components (42)

Bioassays (51)

Research

Studies (82)

Market Indicators

Research Demand Index: 33.72

Study Types

rocaglamide

Description

Related Flora

Cross-References

Synonyms (41)

Research Excerpts

Overview

Effects

Actions

Treatment

Roles (3)

Drug Classes (3)

Protein Targets (11)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (204)

Molecular Functions (66)

Ceullar Components (42)

Bioassays (51)

Research

Studies (82)

Market Indicators

Research Demand Index: 33.72

Study Types

Related Drugs (71)

Related Conditions (57)